Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Nanjing's TransThera Granted US Fast Track for Cholangiocarcinoma Therapy

publication date: Nov 4, 2021

TransThera Sciences (Nanjing) has been granted US Fast Track Designation for its Phase II Cholangiocarcinoma (CCA) therapy. TT-00420 is a spectrum selective kinase inhibitor that has shown high potency against a variety of clinically identified FGFR2 mutations. The FTD is based on positive clinical results from a Phase I study of TT-00420. In 2019, TT-00420 was granted US Orphan Drug Designation for Cholangiocarcinoma. TransThera develops small molecule drug therapies for oncology, inflammatory and cardiovascular diseases. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital